NCT05142423 - A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

198

Participants

Timeline

Start Date

November 3, 2021

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions

Advanced Solid Tumor

Interventions

DRUG

AK109+AK104

It includes dose escalation and dose expansion stage. 6-12 patients will be enrolled in dose escalation stage for safety and efficacy. Then select specific dose of AK104 and AK109. Expand for the further safety and efficacy study.

Trial Locations (1)

Unknown

RECRUITING

First affliated hospital of Zhejiang University, Hangzhou